Guide of practical clinic for the handling of the renal chronic disease in the adult
Keywords:
CLINICAL PRACTICE GUIDELINE, CHRONIC KIDNEY DISEASE, PRIMARY HEALTH CARE, INTERVENTION.Abstract
Introduction: chronic kidney disease constitutes a health problem because of its impact on individuals, society and the economy.
Objective: to design a clinical practice guideline for the management of chronic kidney disease in primary health care.
Methods: clinical epidemiological research was carried out between 2019-2021, at the “Luis Augusto Turcios Lima” University Teaching Polyclinic, in the municipality of Pinar del Río. The guide was elaborated by evidence-based medicine, consensus and expert opinion. The Microsoft Excel 2016 program was used for the collection and processing of the information. The quality assessment was performed with the AGREE (Appraisal of Guidelines, Research and Evaluation for Europe) Instrument.Development: 968 scientific articles were chosen, of which 490 were finally included in the guideline, classified as follows: 43 meta-analyses and systematic reviews of clinical trials, 39 clinical trials, five meta-analyses and systematic reviews of cohort studies, four systematic reviews of qualitative studies, 152 cohort studies, 22 case-control studies, 16 cross-sectional and longitudinal observational studies, two quasi-experimental studies, 22 qualitative studies, 143 updated reviews, 35 clinical practice guidelines and four expert opinions.
Conclusions: a guide was designed to improve the quality of life of patients with chronic kidney disease in primary health care. Preventive practices and early detection of the disease were systematized. The guideline was finally evaluated by experts as "Highly recommended.
Downloads
References
1. Grill AK, Brimble S. Approach to the detection and management of chronic kidney disease Can FAM Physician [Internet]. 2018 [citado 4/12/2022]; 64(10): 728-35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6184972/
2. Weckmann, et al. Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines BMC Nephrology [Internet]. 2018 [citado 4/12/2022]; 19(1): 258. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180496/
3. Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury. Nat Rev Dis Primers [Internet]. 2021 [citado 4/12/2022]; 7(1): 52. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34267223/
4. [Guía Salud] Grupo de trabajo para la actualización del Manual de Elaboración de GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Actualización del Manual Metodológico 2016 [Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2016 [citado 4/12/2022]. Disponible en: http://portal.guiasalud.es/emanuales/elaboracion_2/Capitulos/completo.pdf
5. Durrer Schutz D, Busetto L, Dicker D. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts [Internet]. 2019 [citado 4/12/2022]; 12(1): 40-66. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465693/
6. Jalalonmuhali M, Lim SK, Shah MN, et al. MDRD vs. CKD-EPI in comparison to (51) Chromium EDTA: a cross sectional study of Malaysian CKD cohort. BMC Nephrol [Internet]. 2017 [citado 4/12/2022]; 18(1): 363. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729257/
7. Rodríguez-Ramos J, Herrera-Miranda G. Factores de riesgo relacionados con enfermedad renal crónica. Policlínico Luis
A. Turcios Lima, Pinar del Río, 2019. Medisur [Internet]. 2022 [citado 12/01/2022]; 20(1): 59-66. Disponible en:
http://medisur.sld.cu/index.php/medisur/article/view/5053
8. González-Milán ZC, Escalona-González SO, Díaz-Pérez MJ, Laborí-Quesada P, Mulet-Duarte A, Pavón-Rojas AJ. Detección de enfermedad renal crónica oculta mediante determinación de albuminuria en pacientes con diabetes mellitus. Rev Cubana Med Gen Integr [Internet]. 2021 Dic [citado 20/06/2023]; 37(4): e1539. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252021000400007&lng=es.
9. LeRoith D, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline J Clin Endocrinol Metab [Internet]. May 2019 [citado 20/06/2023]; 104(5): 1520–1574. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271968/
10. Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis. Kidney Blood Press Res [Internet]. 2018 [citado 20/06/2023]; 43(3): 768-779. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29794446/
11. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol [Internet]. 2019 [citado 20/06/2023]; 7(2): 128-139. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30635226/
12. Baliker M, et al. Change in estimated GFR and albuminuria as end points in clinical trials: a perspective of people living with kidney disease. Am J Kidney Dis [Internet]. 2020 [citado 20/06/2023]; 75(1): 4-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31672253/
13. Zabeen B, Nahar J, Islam N, Azad K, Donaghue K. Risk factors associated with microalbuminuria in children and adolescents with diabetes in Bangladesh. Indian J Endocrinol Metab [Internet]. 2018 [citado 20/06/2023]; 22(1): 85-88. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838918/
14. Coresh J, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol [Internet]. 2019 [citado 20/06/2023]; 7(2): 115-127. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30635225/
15. Chen CH, et al. Proteinuria as a Therapeutic Target in Advanced Chronic Kidney Disease: a Retrospective Multicenter Cohort Study. Sci. Rep [Internet]. 2016 [citado 20/06/2023]; 6: 26539. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873744/
16. Thompson A, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol [Internet]. 2019 [citado 20/06/2023]; 14(3): 469–481. Disponible en: https://cjasn.asnjournals.org/content/clinjasn/14/3/469.full.pdf
17. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet [Internet]. 2019 [citado 20/06/2023]; 393(10184): 1937-1947. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30995972/
18. Donate-Correa J, et al. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. J. Clin. Med [Internet]. 2019 [citado 20/06/2023]; 8: 287. Disponible en: https://pdfs.semanticscholar.org/8c50/4bfd4f3883987e47fc3fb62af5294b952d6e.pdf
19. American Diabetes Association. Standards of Medical Care in Diabetes−2019. Diabetes Care [Internet]. 2019 [citado 20/06/2023]; 37(1): 11–34. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336119/
20. Hernández-Jiménez S, García-Ulloa AC, Bello-Chavolla OY, Aguilar-Salinas CA, Kershenobich-Stalnikowitz D, Group of Study CAIPaDi. Longterm effectiveness of a type 2 diabetes comprehensive care program. The CAIPaDi model. Diabetes Res Clin Pract [Internet]. 2019 May [citado 20/06/2023]; 151: 128-137. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30954513/
21. Shlipak MG, Tummalapalli SL, Boulware LB, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int [Internet]. 2021 January 01 [citado 20/06/2023]; 99(1): 34-47. Disponible en: https://www.kidney-international.org/article/S0085-2538(20)31210-2/fulltext
22. Duan JY, Duan GC, Wang CJ, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey. BMC Nephrol [Internet]. 2020 [citado 20/06/2023]; 21: 115. Disponible en: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01761-5#citeas
23. Cebrian A, Escobar C, Aranda U, Palacios B, Capel M, Sicras A, et al. Including KDIGO cardiovascular risk stratification into SCORE scale could improve the accuracy to better stratify cardiovascular risk. Nefrología [Internet]. 2024 [citado 20/06/2023]; 44(2): 292-294. Disponible en: https://www.sciencedirect.com/science/article/pii/S0211699521002812
24. Kam-Tao Li1 P, Garcia-Garcia G, Siu-Fai L, Andreoli S, Wing-Shing Fung W. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Can J Kidney Health Dis [Internet]. 2020 [citado 20/06/2023]; 7: 226-32. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066467/
25. Knuuti J, Wijns W, Saraste A, et al. The Task Force ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal [Internet]. 2020 [citado 20/06/2023]; 41(3): 407-47. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31504439/
26. Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol [Internet]. 2020 [citado 20/06/2023]; 12(1): 7-25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31984124/
27. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int [Internet]. 2021 [citado 20/06/2023]; 99(3S): S1–S87. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33637192/
28. Pajewski NM, Berlowitz DR, Bress AP, et al. Intensive vs standard blood
pressure control in adults 80 years or older: a secondary analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc [Internet]. 2020 [citado 20/06/2023]; 68(3): 496–504. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31840813/
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
